IDORSIA LTD |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.264 CHF | +1.62% |
|
-10.21% | +7.38% |
| Jun. 03 | Idorsia Ltd. Announces New Data with Daridorexant to Be Presented at Sleep 2024 | CI |
| May. 21 | Idorsia Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 114M 128M | Sales 2025 * | 210M 236M | Capitalization | 401M 450M |
|---|---|---|---|---|---|
| Net income 2024 * | -397M -445M | Net income 2025 * | -355M -398M | EV / Sales 2024 * | 12.2 x |
| Net Debt 2024 * | 993M 1.11B | Net Debt 2025 * | 1.09B 1.22B | EV / Sales 2025 * | 7.1 x |
| P/E ratio 2024 * |
-1.58
x | P/E ratio 2025 * |
-2.03
x | Employees | 650 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on Idorsia Ltd
More recommendations
More press releases
More news
| 1 day | -5.83% | ||
| 1 week | -5.19% | ||
| Current month | -14.11% | ||
| 1 month | +10.74% | ||
| 3 months | +27.31% | ||
| 6 months | +13.21% | ||
| Current year | +5.39% |
1 week
2.23
2.70
1 month
2.022.70
Current year
1.293.70
1 year
1.298.47
3 years
1.2927.08
5 years
1.2933.88
10 years
1.2933.88
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
André Muller
DFI | Director of Finance/CFO | 60 | 17-05-31 |
Martine Clozel
CTO | Chief Tech/Sci/R&D Officer | 68 | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jörn Aldag
BRD | Director/Board Member | 65 | 20-05-12 |
Peter Kellogg
BRD | Director/Board Member | 67 | 21-05-11 |
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 746 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 2.27 | +1.89% | 93 250 |
| 24-06-05 | 2.228 | -5.83% | 533,834 |
| 24-06-04 | 2.366 | -10.72% | 977,657 |
| 24-06-03 | 2.65 | +2.16% | 1,542,244 |
| 24-05-31 | 2.594 | +2.61% | 505,160 |
Delayed Quote Swiss Exchange, June 05, 2024 at 11:31 am EDT
More quotes
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
2024-06-13
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.228
CHF
Average target price
1.692
CHF
Spread / Average Target
-24.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.39% | 448M | |
| +18.72% | 125B | |
| +14.53% | 109B | |
| -2.88% | 24.74B | |
| +2.18% | 22.67B | |
| -10.09% | 18.14B | |
| -41.04% | 16.67B | |
| -11.83% | 16.64B | |
| +1.46% | 13.45B | |
| +24.22% | 11.32B |
- Stock Market
- Equities
- IDIA Stock
